title: Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial.
abstract: Previous studies conducted by our group suggested that the ability to demonstrate an impact of emesis control on quality of life might depend upon when an quality of life instrument was administered in relation to chemotherapy and on the time frame of the questionnaire. This study was conducted to address this issue. Six hundred and fifty patients receiving moderately emetogenic chemotherapy in a randomized trial comparing a variety of anti-emetic regimens were allocated to four different modes of administration (days 4 and 8; 3 and 7 day time frames) of the QLQ-C30. Patients who completed the questionnaire at the time of maximal impact of chemotherapy (day 3) were more likely to report deterioration in quality of life. Patients who completed questionnaires at day 8 were more likely to report deterioration in quality of life if their questionnaire had a 7 day time frame rather than a 3 day time frame. Patients receiving more effective anti-emetic therapy had better quality of life. It was concluded that better anti-emetic control improves quality of life after moderately emetogenic chemotherapy. In studying quality of life in situations where the impact of treatment waxes and wanes, careful attention needs to be paid to scheduling the administration of questionnaires and to their time frame.
authors.affiliation: NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Pater
authors.forename: D
authors.initials: D
authors.lastname: Osoba
authors.forename: B
authors.initials: B
authors.lastname: Zee
authors.forename: W
authors.initials: W
authors.lastname: Lofters
authors.forename: M
authors.initials: M
authors.lastname: Gore
authors.forename: E
authors.initials: E
authors.lastname: Dempsey
authors.forename: M
authors.initials: M
authors.lastname: Palmer
authors.forename: C
authors.initials: C
authors.lastname: Chin
mesh_terms: D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D015982:Bias; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D011795:Surveys and Questionnaires / Q000592:standards*; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy* / Q000523:psychology*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents